Horizon Therapeutics gains on report about Amgen potential deal close on May 23
JHVEPhoto/iStock Editorial via Getty Images

Horizon Therapeutics (NASDAQ:HZNP) quickly rose 2% on a report that Amgen's (NASDAQ:AMGN) planned acquisition is expected to close on May 23.
Horizon (HZNP) employees were told to expect a deal close on May 23, according to a Dealreporter item on Friday, which cited an internal email sent to workers.

The Federal Trade Commission hasn't added lawyers to its review since the parties certified with the agency's request for more information earlier this month, according to Dealreporter.
Investors are awaiting a May 22 Irish court hearing for Horizon's (HZNP) planned $28 billion sale to Amgen (AMGN) as well as Federal Trade Commission approval for the deal. Horizon (HZNP) and Amgen (AMGN) in late January confirmed they received a second request from the FTC.
A UBS analyst on Tuesday said that Horizon's (HZNP) earnings miss is "irrelevant" given that the sale to Amgen (AMGN) is still likely to close.

Amgen (AMGN) is set to present at Bofa healthcare conference on Tuesday.